The core problem Recursion seeks to solve is that the process of discovering and making new medicines is becoming slower and more costly over time, despite perpetually increasing knowledge of human ...

Recursion said it will end development for four of its 11 pipeline programs—one of which the company will consider outlicensing to a partner instead—and pause a fifth program, in a pruning designed to ...

One reason Recursion Pharmaceuticals could become a big deal is that its goal is to usher a paradigm shift into the pharmaceutical industry. Even with impressive technological progress over the past ...